Dealmaking makes a comeback as tech giants battle for dominance in artificial intelligence -
Dealmakers in the technology sector have battled headwinds over the past few years. Global deal value sank to US$456.6 billion in...more
Technology continued to drive M&A activity in 2022 despite the odds being stacked against the sector -
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed...more
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
1/30/2023
/ Acquisitions ,
Buyers ,
Capital Markets ,
CFIUS ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Department of Justice (DOJ) ,
Domestic Dealmaking ,
Environmental Social & Governance (ESG) ,
EU ,
Federal Trade Commission (FTC) ,
Financial Institutions ,
Financial Services Industry ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Real Estate Market ,
Securities and Exchange Commission (SEC) ,
Sellers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
Dealmaking activity in the US healthcare sector was robust in H1 2022 in the face of various macroeconomic headwinds. There were US$92.4 billion worth of deals announced in H1 2022. This was a 51 percent decrease from a...more
The technology sector continued to be the driving force behind US dealmaking in H1 2022. A total of 1,299 deals valued at US$415.4 billion took place in the US tech sector in H1 2022, maintaining tech's status as the most...more
Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity -
Healthcare and pharmaceutical deals continued at a robust pace through 2021, registering the...more
2/3/2022
/ Acquisitions ,
CFIUS ,
Domestic Dealmaking ,
Healthcare ,
Initial Public Offering (IPO) ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
Technology M&A activity is thriving in 2021 as dealmakers continue to turn to the sector in search of assets with high-quality earnings and growth prospects -
Technology deal volume and value surged through the first half...more
7/30/2021
/ Acquisitions ,
Antitrust Division ,
Biden Administration ,
Digital Health ,
Domestic Dealmaking ,
Global Dealmaking ,
Healthcare ,
Mergers ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs) ,
Technology Sector